Imaging Liver Metastases with a New Oral Manganese-Based Contrast Agent

Academic Radiology

Volumn 13, Issue 7, 2006, Pages 827-832

  Chabanova, Elizaveta ^a   Logager, Vibeke ^a   Moller, Jakob M ^a   Dekker, Hellen ^b   Barentsz, Jelle ^b   Thomsen, Henrik S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

liver metastases; liver specific contrast agent; manganese based contrast agent; MRI

Indexed keywords

ALANINE; COLECALCIFEROL; MANGANESE CHLORIDE;

ADULT; ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CHLORIDES; COLONIC NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MANGANESE COMPOUNDS; MIDDLE AGED; NEOPLASM METASTASIS; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 33744966099     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2006.03.013     Document Type: Article

References (12)

1. Bellin M.-F., Webb J.A.W., Van Der Molen A.J., et al. Safety of MR liver specific contrast media. Eur Radiol 15 (2005) 1607-1616
2. Martin D.R., and Semelka R.C. Magnetic resonance imaging of liver. review of techniques and approach for common diseases. Semin Ultrasound CT MR 26 (2005) 116-131
3. Balci N.C., and Semelka R.C. Contrast agents for MR imaging of the liver. Radiol Clin N Am 43 (2005) 887-898
4. Reimer P., Schneider G., and Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of liver. properties, clinical development and applications. Eur Radiol 14 (2004) 559-578
5. Korc M. Manganese homeostasis in humans and its role in disease states. In: Korc M. (Ed). Essential and toxic trace elements in human health and disease (1988), Alan R. Liss, New York, NY 253-273
6. Thomsen H.S., Loegager V., Noergaard H., et al. Oral manganese for liver imaging at three different field strengths. Acad Radiol 11 (2004) 630-636
7. Chabanova E., Thomsen H.S., Loegager V., et al. Effect of new manganese contrast agent on tissue intensities. comparison of 0.23 T, 0.6T and 1.5 T MRI. A part of a phase I trial. Magma 17 (2004) 28-35
8. Thomsen H.S., Svendsen O., and Klastrup S. Increased manganese concentration in the liver after oral intake. Acad Radiol 11 (2004) 38-44
9. Kim M.J., Kim J.H.K., Lim J.S., et al. Detection and characterization of focal hepatic lesions. mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Res Imaging 20 (2004) 612-621
10. Sahani D.V., Kalva S.P., Fischman A.J., et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas. comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 185 (2005) 239-246
11. Oudkerk M., Torres C.G., Song B., et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging. multicenter study comparing MR and dual-phase CT. Radiology 223 (2002) 517-524
12. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466